Issue Date: June 17, 2013
Pushing Cancer Over The Edge
A class of experimental drugs staged a quiet comeback last month at the American Society of Clinical Oncology’s annual meeting, held in Chicago. A cluster of studies suggested that compounds that block PARP, an enzyme involved in DNA repair, could be useful in treating ovarian and breast cancers driven by a mutation in BRCA, a gene that recently made headlines when actress Angelina Jolie revealed she carried the mutation.
The data presented at the ASCO . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society